We are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. While enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. Cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. Our goal is nothing less than to develop curative cell-based therapies for any solid tumor cancer.
Location: United States, Washington, Seattle
Employees: 201-500
Founded date: 2018
Investors 4
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| - | 8VC | 8vc.com |
| - | WRF Capita... | wrfseattle... |
| 16.09.2024 | Axial VC | axialvc.co... |
Mentions in press and media 7
| Date | Title | Description |
| 12.01.2026 | Vibrant Therapeutics: $61 Million Closed And Han Lee Named As Co-CEO | Vibrant Therapeutics, a clinical-stage biotech developing “logic-gated” therapeutics designed to activate selectively in diseased tissue, announced it has raised $61 million in new financing and appointed Han Lee, Ph.D. as co-chief executiv... |
| 05.03.2024 | Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting | - |
| 21.12.2022 | Tech Moves: Meta exec joins AI startup, Lyell Immunopharma hires new CEO; and more | Claudiu Bulai. (Quantarium Photo) — Claudiu Bulai is now chief innovation officer at Bellevue, Wash.-based startup Quantarium. Bulai previously spent five years at Meta, most recently leading engineering for the tech giant’s Reality Labs Re... |
| 10.06.2021 | Will legislation on competing with China spur the next big thing akin to the internet? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Earlier this week, the U.S. Senate passed bipartisan legislation aimed at boosting the country’s ... |
| 18.05.2021 | The 24 billion-dollar startups to watch that are revolutionizing healthcare in 2021 | The Tempus lab. Tempus This story is available exclusively to Insider subscribers. Become an Insider and start reading now. The financial fallout of the coronavirus pandemic didn't dampen interest in healthcare startups. Healthcare startups... |
| 05.04.2021 | Outpace Bio Raises $30 Million To Design Next Generation Cell Therapies | Marc Lajoie, CEO of OutpaceOutpace Bio |
| 25.02.2021 | Biotech and healthtech firm Foresite Capital raises $969M new fund | The firm, which now has over $4 billion in assets under management, invests across all stages The biotech space has been growing in the last few years: according to Pitchbook, the space was on track to see more than $20 billion invested in ... |